CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...
CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.
Stifel cuts CRISPR Therapeutics target to $49, holds rating
Stifel analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP), currently trading at $43.09 with a market capitalization of $3.7 billion, reducing the price target to $49 from the ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Crispr Therapeutics price target lowered to $49 from $53 at Stifel
Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the ...
PharmiWeb20h
Breast Cancer Therapeutics Market (2024-2035)
Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...